MT. KISCO, N.Y., June 01, 2016 (GLOBE NEWSWIRE) -- ImmuDyne (OTCQB:IMMD) announced today the appointment of Messrs. Adam
Lefton and Michael Levin to a newly-formed advisory board formed to explore further commercialization opportunities for the
Company's proprietary oral beta-glucan products.
Adam Lefton previously served as Chief Marketing Officer for Nobilis Health Corp. (TSX:NHC) (NYSE:HLTH) (f/k/a Northstar
Healthcare Inc.), an ambulatory surgical center group. Prior to Nobilis, Mr. Lefton was Vice President of Brand Strategy at Cancer
Treatment Centers of America (CTCA), where he helped build one of the most successful hospital-based direct to consumer marketing
programs in the United States.
Michael D. Levin has over 40 years of healthcare industry experience and expertise in business development and regulatory
affairs having served as President at Bergstrom Nutrition (f/k/a Cardinal Nutrition), a leading global supplier of GRAS dietary
ingredients, VP at Baxter Healthcare and an advisory board member at the dietary supplement subsidiary of Cancer Treatment Centers
of America.
"We have long held the belief that our beta-glucan is an effective solution to large unmet needs in healthcare. We have
appointed two highly-experienced executives to spearhead an advisory board that will be tasked with developing a strategy to
address these needs with our solutions," stated Mark McLaughlin, CEO and President of ImmuDyne.
About ImmuDyne
ImmuDyne, Inc. (the “Company”) develops, manufactures and sells natural immune support products containing the Company’s
proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through
testing and analysis to support the immune system. The Company’s products include once a day oral intake capsules, as well as
topical serums and creams for skin application. ImmuDyne also has developed a proprietary natural delivery technology with
potential new market opportunities. All of ImmuDyne’s intellectual property is protected by patents and/or trade secrets.
Additional information can be found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release
are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this
press release, including projections with respect to ImmuDyne’s results of operations, may contain words such as "anticipates,"
"believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are
considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts.
These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and
therefore the actual results may be materially different from those discussed.
Contact: ImmuDyne, Inc. Mark McLaughlin: +1-914-714-8901